Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Iterum Therapeutics plc is a clinical-stage pharmaceutical company focused on the development and commercialization of novel anti-infective therapies to address drug-resistant bacterial pathogens. The company operates within the biopharmaceutical and anti-infectives industries, with a primary emphasis on treatments for serious and life-threatening infections where resistance to existing antibiotics presents significant clinical challenges.
The company’s core asset is sulopenem, a next-generation beta-lactam antibiotic being developed in both oral and intravenous formulations. Iterum’s strategy centers on targeting multidrug-resistant gram-negative bacteria, particularly in urinary tract infections. Iterum Therapeutics plc was founded in 2015 through the combination of Iterum Therapeutics International Limited and the infectious disease business of Pfizer Inc., acquiring rights to sulopenem and related intellectual property. The company is incorporated in Ireland and is publicly traded on the Nasdaq under the ticker ITRM.
Business Operations
Iterum Therapeutics operates as a single-segment company focused on anti-infective drug development, with no commercialized products to date. Revenue generation has historically consisted of collaboration revenue, licensing arrangements, and interest income rather than product sales, reflecting its clinical-stage status. The company’s development efforts are primarily concentrated on regulatory approval pathways for sulopenem, including interactions with the U.S. Food and Drug Administration.
Operational activities include clinical trial management, regulatory strategy, manufacturing coordination through third-party contract manufacturers, and intellectual property management. Iterum does not operate its own manufacturing facilities and relies on external partners for clinical supply and potential future commercial production. The company conducts research and development activities in the United States and Europe, supported by a lean internal organization and outsourced service providers.
Strategic Position & Investments
Iterum’s strategic direction is focused on advancing sulopenem toward regulatory approval and identifying potential partnering or commercialization opportunities in key markets. The company has invested heavily in late-stage clinical trials aimed at demonstrating non-inferiority to existing therapies for uncomplicated and complicated urinary tract infections, including infections caused by resistant pathogens.
The company does not maintain a diversified portfolio of marketed products or multiple pipeline assets, making sulopenem its primary value driver. Strategic efforts have included restructuring initiatives and capital management actions to extend cash runway while pursuing regulatory pathways. Iterum has not announced significant acquisitions in recent years and does not control a portfolio of operating subsidiaries beyond its wholly owned development entities, including Iterum Therapeutics International Limited.
Geographic Footprint
Iterum Therapeutics plc is headquartered in Ireland, with principal executive and operational functions conducted in the United States, particularly in Massachusetts. The company’s clinical development programs have involved trial sites across North America and Europe, reflecting its focus on regulatory approvals in major pharmaceutical markets.
While Iterum does not maintain a commercial sales presence, its geographic footprint reflects international regulatory engagement and global clinical development. The company’s strategic focus remains primarily on the United States and European Union, which represent the largest potential markets for its lead anti-infective candidate.
Leadership & Governance
Iterum Therapeutics is led by an executive team with experience in anti-infective drug development, regulatory strategy, and pharmaceutical commercialization. The leadership emphasizes capital discipline, regulatory execution, and addressing unmet medical needs in infectious diseases through targeted antibiotic innovation.
Key executives include:
- Corey N. Fishman – Chief Executive Officer
- William F. DeGrado – President and Chief Scientific Officer
- David J. Barrett – Chief Financial Officer
- Patrick Healy – Chief Medical Officer
The board of directors and management team collectively guide the company’s strategic vision, focusing on advancing sulopenem through regulatory milestones while managing the risks inherent in clinical-stage pharmaceutical development.